Genetic Determinants of Warfarin Maintenance Dose and Time in Therapeutic Treatment Range: A RE-LY Genomics Substudy | Zendy

Niclas Eriksson | Zendy; Lars Wallentin | Zendy; Lars Berglund | Zendy; Tomas Axelsson | Zendy; Stuart J. Connolly | Zendy; John W. Eikelboom | Zendy; Michael D. Ezekowitz | Zendy; Jonas Oldgren | Zendy; Guillaume Paré | Zendy; Paul Reilly | Zendy; Agneta Siegbahn | Zendy; Ann-Christine Syvänen | Zendy; Claes Wadelius | Zendy; Salim Yusuf | Zendy; Mia Wadelius | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetic Determinants of Warfarin Maintenance Dose and Time in Therapeutic Treatment Range: A RE-LY Genomics Substudy

Author(s) -

Niclas Eriksson,

Lars Wallentin,

Lars Berglund,

Tomas Axelsson,

Stuart J. Connolly,

John W. Eikelboom,

Michael D. Ezekowitz,

Jonas Oldgren,

Guillaume Paré,

Paul Reilly,

Agneta Siegbahn,

Ann-Christine Syvänen,

Claes Wadelius,

Salim Yusuf,

Mia Wadelius

Publication year - 2016

Publication title -

pharmacogenomics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.541

H-Index - 91

eISSN - 1744-8042

pISSN - 1462-2416

DOI - 10.2217/pgs-2016-0061

Subject(s) - vkorc1 , cyp2c9 , warfarin , single nucleotide polymorphism , genome wide association study , snp , medicine , maintenance dose , vitamin k epoxide reductase , therapeutic index , biology , genetics , pharmacology , gene , atrial fibrillation , genotype , drug

We investigated associations between genetic variation in candidate genes and on a genome-wide scale with warfarin maintenance dose, time in therapeutic range (TTR), and risk of major bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research